Kangxinuo Biological Co., Ltd. was registered in Tianjin Binhai New Area in 2009. It is a national high-tech enterprise founded by the senior management team of multinational pharmaceutical companies. Kangxinuo Bio is committed to providing solutions to prevent infectious diseases and infectious diseases on a global scale, specializing in the research, development, production and commercialization of high-quality human vaccines, and is a leading high-tech biological product enterprise in China.
2065438+In March 2009, Kangxinuo Bio was listed on the main board of Hong Kong Stock Exchange. In June 5438 +2020 10, the company formally submitted an application for listing on the Science and Technology Innovation Board, which was accepted. It is planned to raise funds to expand the production capacity of new vaccines and develop new vaccine products.
The R&D team of Kangxinuo Bio has gathered many famous scientists and senior experts in the vaccine industry who have led innovative international vaccine research and development in the world's large pharmaceutical companies such as Sanofi Pasteur, AstraZeneca and Wyeth (now Pfizer), and established four core technology platforms based on adenovirus vector vaccine technology, protein structural design and recombination technology, combination technology and preparation technology.
The company has a number of vaccine core intellectual property rights and proprietary technologies, and has established a 16 innovative vaccine product research and development assembly line in the field of 13 diseases, covering the prevention of a series of diseases such as novel coronavirus, Ebola virus disease, tuberculosis, meningitis, whooping cough and herpes zoster.